An epigenome-wide association study in whole blood of measures of adiposity among Ghanaians: the RODAM study by Meeks, Karlijn A.C. et al.
RESEARCH Open Access
An epigenome-wide association study in
whole blood of measures of adiposity
among Ghanaians: the RODAM study
Karlijn A.C. Meeks1*, Peter Henneman2, Andrea Venema2, Tom Burr3, Cecilia Galbete4, Ina Danquah4,5,
Matthias B. Schulze4, Frank P. Mockenhaupt6, Ellis Owusu-Dabo7, Charles N. Rotimi8, Juliet Addo9, Liam Smeeth9,
Silver Bahendeka10, Joachim Spranger11,12,13, Marcel M.A.M. Mannens2, Mohammad H. Zafarmand1,
Charles Agyemang1 and Adebowale Adeyemo8*
Abstract
Background: Epigenome-wide association studies (EWAS) have identified DNA methylation loci involved in
adiposity. However, EWAS on adiposity in sub-Saharan Africans are lacking despite the high burden of adiposity
among African populations. We undertook an EWAS for anthropometric indices of adiposity among Ghanaians
aiming to identify DNA methylation loci that are significantly associated.
Methods: The Illumina 450k DNA methylation array was used to profile DNA methylation in whole blood samples
of 547 Ghanaians from the Research on Obesity and Diabetes among African Migrants (RODAM) study. Differentially
methylated positions (DMPs) and differentially methylation regions (DMRs) were identified for BMI and obesity
(BMI ≥ 30 kg/m2), as well as for waist circumference (WC) and abdominal obesity (WC ≥ 102 cm in men, ≥88 cm in
women). All analyses were adjusted for age, sex, blood cell distribution estimates, technical covariates, recruitment
site and population stratification. We also did a replication study of previously reported EWAS loci for
anthropometric indices in other populations.
Results: We identified 18 DMPs for BMI and 23 for WC. For obesity and abdominal obesity, we identified three and
one DMP, respectively. Fourteen DMPs overlapped between BMI and WC. DMP cg00574958 annotated to gene
CPT1A was the only DMP associated with all outcomes analysed, attributing to 6.1 and 5.6% of variance in obesity
and abdominal obesity, respectively. DMP cg07839457 (NLRC5) and cg20399616 (BCAT1) were significantly associated
with BMI, obesity and with WC and had not been reported by previous EWAS on adiposity.
Conclusions: This first EWAS for adiposity in Africans identified three epigenome-wide significant loci
(CPT1A, NLRC5 and BCAT1) for both general adiposity and abdominal adiposity. The findings are a first step in
understanding the role of DNA methylation in adiposity among sub-Saharan Africans. Studies on other sub-Saharan
African populations as well as translational studies are needed to determine the role of these DNA methylation
variants in the high burden of adiposity among sub-Saharan Africans.
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Background
Adiposity is a major risk factor for non-communicable
diseases such as cardiovascular disease and type 2 dia-
betes [1]. It is more prevalent among African residents
in Europe compared with the European host population,
in particular among women [2]. Furthermore, both obes-
ity (body mass index (BMI) ≥ 30 kg/m2) and abdominal
obesity (waist circumference (WC) ≥ 88 cm for women
and ≥ 102 cm for men) prevalence have been shown to
be much higher in African populations resident in
Europe compared with their compatriots in urban and
rural Africa. In rural Ghana, the obesity and abdominal
obesity prevalence were respectively 5.4 and 19.3% com-
pared with 25.7 and 42.4% in urban Ghana, and 35.6 and
50.5% among Ghanaians resident in Europe [3].
Adiposity results from a wide range of underlying risk
factors, including genetic and environmental factors.
Genome-wide association studies (GWAS) have identi-
fied many genetic risk variants associated with obesity
and/or BMI [4]. However, these loci only account for a
few percent of variation in BMI [4]. The explained herit-
ability is thought to be low due to a strong effect of
environment and lifestyle on BMI [5]. This strong envir-
onmental effect is thought to be the “obesogenic” envir-
onment, i.e. an environment that predisposes to obesity
on a large scale. The obesogenic environment comprises
multiple layers such as household, neighbourhood, city
and country level [6]. For example, obesogenic attributes
on a country level include food availability and exposure
to food advertisements. BMI heritability has been shown
to be lower in countries with relatively few obesogenic
attributes (partly from lower gross domestic product and
consumption), as is still the case in many low- and
middle-income countries [7].
An important product of gene-environmental inter-
action is thought to involve epigenetic mechanisms [8].
Epigenetics comprises cellular mechanisms that regulate
gene expression, such as chromatin remodelling, histone
modifications and DNA methylation [9]. The latter in-
volves the binding of methyl groups to CpG dinucleo-
tides in the DNA and is the most frequent studied
epigenetic mechanism. DNA methylation can be influ-
enced by environmental exposures such as climate [10]
and by health-related behaviours such as smoking, diet
and physical activity [9]. Hence, epigenetics is a means
by which genes and environment can interact. Epigenetic
modifications, such as DNA methylation changes, can
therefore be a consequence of environment, a conse-
quence of genetics or a consequence of both. A defining
feature of epigenetics is that it is reversible [10] and
could therefore provide potential targets for prevention
and intervention. Epigenome-wide association studies
(EWAS) have identified epigenetic loci potentially in-
volved in adiposity [11–18]. Despite the increased risk of
African ancestry populations for adiposity, only two pre-
vious EWAS on adiposity have been conducted in such
populations, and these studies were conducted in African
Americans [14, 18]. However, African American popula-
tions differ from sub-Saharan Africans in environment as
well as in genetics (they are an African-European genetic-
ally admixed population) [19]. To the best of our know-
ledge, there are no data on epigenetics in relation to
adiposity among sub-Saharan Africans.
In the present study, we aimed to identify epigenetic
loci associated with generalized obesity as indicated by
BMI and abdominal obesity as indicated by waist cir-
cumference (WC), among Ghanaians using the Human
Methylation 450K platform of Illumina.
Methods
Study population
The present analysis is based on the Research on Obes-
ity and Diabetes among African Migrants (RODAM)
study, of which the study design and data collection are
described in detail elsewhere [3, 20]. In brief, the
RODAM study collected data between 2012 and 2015
on a relatively homogenous population of sub-Saharan
Africans, i.e. Ghanaians. In total, 6385 Ghanaians were
recruited from rural Ghana (15 villages in Ashanti re-
gion), urban Ghana (Kumasi and Obuasi), London,
Amsterdam and Berlin. From the total RODAM study
population, a subset of 736 individuals was selected with
a BMI range from 15.8 to 51.8 kg/m2. For the current
analyses, individuals who self-reported having type 2
diabetes (n = 128) were excluded. These individuals are
more likely to have engaged in weight loss activities be-
cause the standard of care and clinical guidelines for
type 2 diabetes at the study sites include dietary and ex-
ercise intervention both in Ghana [21] and Europe [22].
After additional exclusions (as described below and in
the Additional file 1), the final sample size for this ana-
lysis was 547. This sample size has over 80% power to
detect a 6% difference in methylation with epigenome
wide significance between those with generalized obesity
(BMI ≥ 30 kg/m2) and those without (BMI < 30 kg/m2)
and an 8% difference in methylation between those with
abdominal obesity and those without [23].
Phenotypic measurements
Information on demographics and self-reported health
were collected by self- or interviewer-administered ques-
tionnaire. Participants were physically examined, includ-
ing measurements of weight, height and WC. Height
(SECA 217 stadiometer) and weight (SECA 877 scale)
were measured in light clothing, and BMI was calculated
as weight/height2 (kg/m2). WC was measured in light
clothing at the level midway between the lower rib
margin and the iliac crest. Both generalized adiposity
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and abdominal adiposity were examined. Generalized adi-
posity was defined by BMI as this is the most wide-spread
measure used to assess generalized adiposity. To facilitate
interpretation for clinical practice, BMI was dichotomised
into a binary generalized adiposity measure—obesity—de-
fined as a BMI of ≥ 30.0 kg/m2 according to the World
Health Organization (WHO) definition [24]. WC was used
as measure for abdominal obesity and was dichotomised
following WHO recommendations, i.e. abdominal obesity
is WC ≥ 88 cm for women and ≥ 102 cm for men [25].
DNA profiling, processing and quality control
Fasting blood samples were collected by trained research
assistants and shipped to Source Bioscience Nottingham
for DNA extraction, genotyping and DNA methylation
profiling.
Bisulfite treatment of DNA (Zymo EZ DNA Methyla-
tionTM kit) was used to deaminate unmethylated cyto-
sine to produce uracil in DNA conform manufacturer’s
protocol. The converted DNA was amplified and hybrid-
ized on the Illumina Human Methylation 450K array
which quantifies DNA methylation levels of approxi-
mately 485,000 CpG sites. The samples were divided
over eight bisulfite conversion and hybridization batches.
Raw 450K data were processed for primary quality control
using the statistical software platform “R” (version 3.2.2)
and the MethylAid package (version 1.4.0). An overview of
R packages used can be found in Additional file 1: Table S1.
MethylAid detects poor-quality samples using sample-
dependent and sample-independent control CpG sites
present on the 450K array itself [26]. MethylAid threshold
values included methylated and unmethylated intensities of
10.5, overall quality control of 11.75, bisulfite control of
12.75, hybridization control of 12.50 and a detection p value
of 0.95. Based on these thresholds, 12 samples were
considered outliers (Additional file 1: Figure S1-B).
To check for potential population stratification, princi-
pal component analysis (PCA) was done using PLINK 1.9
[27] on genotypes obtained from the African Diaspora
Power Chip (ADPC). Evaluation of the scree plot
(Additional file 1: Figure S1-A) combined with formal
testing for significant PCs using the minimum average
partial test [28] revealed only PC 1 as a significant
PC. This first PC was included in the genome-wide
epigenetic association models to adjust for possible
residual population stratification. Although PC 2 and
PC 3 accounted for moderate amounts of the total
variance, the addition of PC 2 and PC 3 in associ-
ation models did not further improve or significantly
alter our results. Therefore, PC 2 and PC 3 were not
included in our final models (data not shown). Geno-
typing data (not reported here) revealed eight samples
with a sex discordance compared with the phenotype
data that were subsequently excluded.
Functional normalization was applied using the “R”
minfi package to normalize raw 450K data. PCA on the
normalized 450K dataset annotated for sex, recruitment
site, self-reported ethnic group within Ghana, bisulfite
batch, hybridization batch and array position revealed
three additional gender-discordant samples and some
stratification on array position. No other outliers were
observed in the epigenetics PCA. Sex-discordant sam-
ples detected by genetic and/or epigenetic analyses were
removed. All nonspecific CpG sites were removed [29]
as well as CpG sites located on chromosomes X and Y.
Removal of these CpG sites resulted in a set of 429,459
CpG sites which were used to identify differentially
methylated positions (DMPs) and differentially methyl-
ated regions (DMRs) in linear regression analysis as
described below.
Cell composition of whole blood samples is a source
of variability in DNA methylation and has thereby the
potential to cause confounding [30]. We therefore esti-
mated cell distributions using the method proposed by
Houseman et al. [31] with the reference population as
proposed by Reinius et al. [32] and included estimated
cell type distributions as covariate in the analyses.
Additional file 1: Figure S1-C shows the correlation
between the blood cell distribution estimates and PC 1
to 8 of the EWAS. Although observed correlations be-
tween cell type estimates and any PC (Additional file 1:
Figure S1-C) were weak, cell distributions were added
to the models as covariate because cell distribution
bias remains likely to be present according to previous
reports [31, 33]. The weak correlation between cell
type estimates and the PCs is likely to be due to pres-
ence of other, stronger, confounding factors affecting
both the CpGs involved in cell non-mediated and me-
diated processes. Additional file 1: Figure S1-D shows
the correlation between the other covariates and prin-
cipal component 1 to 8 of the PCA performed on the
normalized 450K data. Since previous reports have
shown a potential link between blood cell distribution
and adiposity parameters [34], we performed multicolli-
nearity analyses. These analyses showed a tolerance statis-
tic and a variance inflation factor (VIF) of both 1.0. We
have therefore no indication for multicollinearity between
cell distribution estimates and adiposity indices.
Statistical analysis
Differentially methylated positions
Linear regression analyses were performed in “R” with
the minfi package using DNA methylation levels as
dependent variable to identify DMPs for BMI and WC,
as well as for obesity and abdominal obesity. Age, sex,
recruitment site, estimated cell distributions, technical
effects (hybridization batch and array position) and the
first principal component from genotyping data were
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included as covariates. Model fitting was evaluated using
QQ-plots (Additional file 1: Figure S2). In GWAS, re-
sults are generally corrected for (genomic) inflation. In
order to address inflation of our analyses, we applied the
recently reported EWAS method by Iterson et al. [35]
(Additional file 1: File S3). False discovery rate (FDR) ad-
justment was used to adjust for multiple testing. A FDR
of 0.05 was considered epigenome-wide significant.
DMPs identified in relation to obesity and abdominal
obesity were subsequently included in logistic regression
models to assess the odds for obesity and abdominal
obesity per 1% increase in DNA methylation of respect-
ive DMPs. The Nagelkerke’s R-squared statistic from the
logistic regression models with and without covariates
was used to calculate trait variance explained by a locus.
The region around these DMPs was visualized using the
coMET “R” package [36].
For all DMP analyses, M values were calculated as
the log2 ratio of the intensities of methylated CpG
site versus unmethylated CpG site. Significant differ-
ences were determined based on M values instead of
beta values as is recommended by Du et al. [37]. Corre-
sponding beta values were reported to facilitate biological
interpretation [37].
Differentially methylated regions
To find DMRs, we fitted similar models to DMP ana-
lyses using the bumphunter function in the minfi pack-
age [38]. We calculated the DMRs with the methylation
cut-off of 0.015 (corresponding to 1.5% difference in beta
values) for obesity and abdominal obesity and with cut-
off 0.0015 and 0.0005 for BMI and WC, respectively.
The DMR methylation cut-offs were optimized based on
observed effect sizes and significance levels in a volcano
plot. Estimates were done using bootstrap with 500 per-
mutations. We defined a DMR as three or more CpG
sites within one cluster. Multiple testing adjustment was
performed using family-wise error rate (FWER). We
filtered CpG sites with FWER < 0.2.
Replication of loci reported in non-African populations
Previously reported loci for multiple anthropometric
indices for adiposity were identified through a litera-
ture search. PUBMED was systematically searched in
April 2016 for all papers on DNA methylation and
adiposity published between January 2013 and April
2016. The search included keywords and MeSH terms
on obesity, BMI, abdominal obesity, WC, DNA methy-
lation and for exclusion keywords on animal models
(Additional file 1: File S4). The search resulted in 498
hits (Additional file 1: Figure S4). Titles and abstracts
were considered eligible when written in English, the
reported outcome was related to obesity, sample size
was at least 10 and data were derived from humans or
human cell lines. Title and abstract screening was per-
formed independently by two co-authors (PH and
KM). All conflicts were discussed and resolved before
proceeding to the next stage. Abstract screening re-
sulted in 52 articles for full-text screening and data
extraction. Twenty-six papers were excluded because
their full texts did not report self-generated results,
found no significant associations or the studies were
not directly related to adiposity outcomes. For each
study reporting candidate CpG sites (n = 26), the fol-
lowing data were extracted: authors, year of publica-
tion, ethnicity, sample size, tissue, candidate gene,
analysis technique, chromosome, position, candidate
CpG site, hypo- or hyper-methylation and trait. After
removal of duplicates, 1027 unique 450k array CpG
sites remained (Additional file 1: File S5).
Pathway enrichment analysis
Pathway analyses were performed using the “WEB-based
GEneSeT AnaLysis Toolkit” (WebGestalt) (www.webges
talt.org). We used the tool to evaluate Biological Process,
Cellular Component and Molecular Function pathways
from the GO terms for the top 100 of the BMI and WC
analyses separately. The following settings were applied:
GO database, hsapiens_gene_symbol, hypergeometric
statistical method, FDR multiple test adjustment, sig-
nificance level q < 0.05, minimum number of genes
for category = 4.
Results
Participant characteristics
The 547 individuals in the analyses had a mean BMI of
26.7 kg/m2 (95% CI 26.2–27.2) and a mean WC of
90.3 cm (95% CI 89.3–91.4) (Table 1). The analysis in-
cluded 290 individuals with obesity and 257 without
obesity. By WC criteria, 422 participants had abdominal
obesity and 164 had normal WC. Those with and with-
out obesity were similar in age and had a similar distri-
bution of men and women. Those with abdominal
obesity were similar in age as compared with those with-
out but were more often female. Blood cell distribution
estimates did not differ between those with and without
obesity and abdominal obesity.
Differentially methylated positions
Eighteen DMPs were found associated with BMI as a con-
tinuous variable (Table 2 and Additional file 1: Figure S6).
In contrast, only three DMPs—cg00574958, cg07839457
and cg20399616—, annotated to genes CPT1A, NLRC5
and BCAT1, respectively, were significantly differen-
tially methylated in those with obesity compared with
those without (Table 2 and Fig. 1). The majority of
DMPs (15 out of 18) were hyper-methylated for higher
BMIs. Hypo-methylated DMPs for higher BMI were
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Table 1 Characteristics of participants included in the analyses
All Obesity No obesity Abdominal obesity No abdominal obesity
n (n = 547) (n = 290) (n = 257) (n = 422) (n = 164)
Age, years 50.5 (49.7–51.3) 50.7 (49.6–51.8) 50.4 (49.2–51.6) 50.4 (49.0–51.8) 50.6 (49.6–51.6)
Male, % 42.2 (38.1–46.4) 50.2 (43.8–56.7) 49.8 (43.3–56.2) 15.2 (11.1–20.4) 84.8 (79.6–88.9)
BMI, kg/m2 26.7 (26.2–27.2) 30.9 (30.5–31.4) 21.9 (21.7–22.2) 31.9 (31.3–32.5) 23.6 (23.3–24.0)
Waist circumference, cm 90.3 (89.3–91.4) 99.4 (98.4–100.5) 80.1 (79.3–80.8) 102.1 (100.9–103.3) 83.4 (82.5–84.3)
Site, %
Rural Ghana 13.9 (11.2–17.1) 5.5 (3.4–8.8) 23.3 (18.6–28.9) 8.9 (5.6–13.7) 16.9 (13.3–21.2)
Urban Ghana 36.4 (32.4–40.5) 31.7 (26.6–37.3) 41.6 (35.7–47.8) 38.4 (32.0–45.3) 35.2 (30.3–40.4)
Amsterdam 20.3 (17.1–23.9) 24.1 (19.5–29.4) 9.7 (6.6–14.0) 21.2 (16.1–27.4) 19.8 (15.9–24.3)
Berlin 10.2 (8.0–13.1) 11.0 (7.9–15.2) 9.3 (6.3–13.6) 5.9 (3.4–10.1) 12.8 (9.6–16.8)
London 19.1 (16.1–22.7) 27.6 (22.7–33.0) 16.0 (12.0–21.0) 25.6 (20.1–32.1) 15.4 (12.0–19.6)
Cell counts, %
CD8+ T cells 10.9 (10.5–11.3) 10.8 (10.3–11.4) 11.1 (10.4–11.7) 10.8 (10.1–11.4) 11.0 (10.5–11.6)
CD4+ T cells 18.5 (18.0–19.0) 18.3 (17.7–18.9) 18.7 (18.0–19.4) 18.2 (17.5–19.0) 18.6 (18.0–19.2)
Natural killer cells 10.9 (10.5–11.4) 11.1 (10.4–11.8) 10.7 (10.1–11.4) 10.8 (10.0–11.6) 11.0 (10.4–11.6)
B cells 10.7 (10.5–11.0) 10.7 (10.3–11.1) 10.8 (10.4–11.2) 10.7 (10.2–11.2) 10.8 (10.4–11.1)
Monocytes 7.9 (7.7–8.1) 7.9 (7.6–8.2) 7.9 (7.6–8.2) 7.9 (7.6–8.3) 7.9 (7.6–8.1)
Granulocytes 44.8 (44.0–45.5) 45.0 (43.9–46.1) 44.4 (43.3–45.5) 45.5 (44.1–46.7) 44.4 (43.4–45.3)
Numbers are in means or percentages with corresponding (confidence intervals)
Table 2 Differentially methylated positions for BMI and obesity (BMI ≥ 30 kg/m2)
BMI Obesity
CpG site CHR Position Nearest genea Featureb Delta
β valuec
p valued FDRd Delta
β valuec
p valued FDRd
cg07839457 16 57023022 NLRC5 TSS1500 0.0071 3.79E − 11 1.63E − 05 0.0711 6.38E − 09 1.37E − 03
cg08818207 6 32820355 TAP1 Body 0.0047 7.66E − 08 1.64E − 02 0.0440 5.61E − 06 2.67E − 01
cg00574958 11 68607622 CPT1A 5′ UTR − 0.0014 1.45E − 07 1.71E − 02 − 0.0189 2.53E − 10 1.09E − 04
cg08099136 6 32811251 PSMB8 Body 0.0033 1.59E − 07 1.71E − 02 0.0321 1.18E − 04 6.62E − 01
cg01309328 6 32811253 PSMB8 Body 0.0029 3.38E − 07 2.91E − 02 0.0315 1.02E − 05 3.19E − 01
cg20399616 12 25055967 BCAT1 Body − 0.0028 4.61E − 07 3.30E − 02 − 0.0297 6.36E − 08 9.10E − 03
cg22107533 15 45028083 TRIM69 TSS1500 0.0037 5.69E − 07 3.49E − 02 0.0330 7.10E − 05 6.41E − 01
cg06820412 5 135386296 TGFBI Body 0.0005 7.22E − 07 3.81E − 02 0.0050 1.63E − 05 3.71E − 01
cg00218406 6 31431407 HCP5 3′ UTR 0.0051 8.03E − 07 3.81E − 02 0.0483 4.34E − 05 5.33E − 01
cg25954539 6 31323677 HLA-B Body 0.0046 1.02E − 06 3.81E − 02 0.0454 2.70E − 05 4.15E − 01
cg23235965 6 30459540 HLA-E Body 0.0026 1.04E − 06 3.81E − 02 0.0270 4.50E − 06 2.42E − 01
cg25178683 17 76976267 LGALS3BP TSS1500 0.0019 1.08E − 06 3.81E − 02 0.0195 7.91E − 05 6.41E − 01
cg08996521 3 50649994 CISH TSS1500 0.0015 1.26E − 06 3.81E − 02 0.0142 1.06E − 05 3.19E − 01
cg04927537 17 76976091 LGALS3BP TSS200 0.0026 1.34E − 06 3.81E − 02 0.0286 6.46E − 06 2.76E − 01
cg05490029 8 79719015 IL7 TSS1500 0.0026 1.45E − 06 3.81E − 02 0.0244 1.80E − 05 3.71E − 01
cg18954700 10 124220854 HTRA1 TSS200 − 0.0015 1.49E − 06 3.81E − 02 − 0.0137 4.74E − 04 8.19E − 01
cg25843003 6 31431312 HCP5 3′ UTR 0.0021 1.51E − 06 3.81E − 02 0.0200 5.98E − 05 6.22E − 01
cg06118217 2 240100998 HDAC4 Body 0.0008 1.72E − 06 4.11E − 02 0.0069 1.11E − 05 3.19E − 01
aCpGs are located in the gene if no distance is indicated
bBased on manifest feature annotation Illumina. IGR, intergenic region
cNegative beta values indicate lower DNA methylation (hypo-methylation) in cases compared with controls
dp values and FDR corresponding to M values. Table is sorted on BMI associated p values. All significant hits for both outcomes are included
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annotated to genes CPT1A, BCAT1 and HTRA1. The
DMPs annotated to CPT1A and BCAT1 were also signifi-
cantly hypo-methylated in those with obesity compared
with those without.
Twenty-three DMPs were associated with WC of
which the majority was hyper-methylated in relation to a
higher WC (Table 3 and Additional file 1: Figure S7).
Figure 2 shows the overlap in DMPs for BMI, WC, obes-
ity and abdominal obesity. The direction of effect for
these DMPs was consistent between adiposity indices.
The odds for the obesity were 0.85, 1.04 and 0.94 for the
DMPs annotated to genes CPT1A, NLRC5 and BCAT1,
respectively (Table 4). The DMP annotated to gene
CPT1A, which was significantly hypo-methylated in indi-
viduals with obesity, was also significantly hypo-methylated
in individuals with abdominal obesity compared with those
without (Table 3 and Additional file 1: Figure S8), with
similar odds (OR = 0.84, 95% CI 0.79–0.90) for abdominal
obesity as for obesity (Table 4). Implementation of the
BACON method for reducing inflation (Additional file 1:
File S3) did in general not result in a decrease of observed
inflation (Additional file 1: Figure S3). In addition, the in-
flation-uncorrected and inflation-corrected FDR ad-
justed p values did not differ substantially, i.e. the
observed genome-wide significant DMPs remained the
same (Additional file 1: Table S3-A and Table S3-B).
The DMPs annotated to genes CPT1A, NLRC5 and
BCAT1, which were associated with three out of four
anthropometric indices studied, combined attributed
to 7.6% of the variance on obesity. 6.1% of variation in
obesity was attributable to CPT1A alone and 5.6% for
abdominal obesity (Table 4). Figures 3, 4 and 5
visualize the region around the DMPs annotated to
CPT1A, NLRC5 and BCAT1. Adjustment for energy
intake and physical activity did not substantially alter
the results (Additional file 1: File S9).
The DMPs cg07839457 (NLRC5) and cg20399616
(BCAT1) have not previously been reported to be asso-
ciated with adiposity. Therefore, we evaluated these
novel CpG sites by checking previously published
EWAS for adiposity for having reported these loci. A
reported nominal p value of < 0.05 at similar direction
of effect was considered as significant. We found that
cg07839457 (NLRC5) was significantly associated with
adiposity in Europeans in visceral adipose tissue
(p = 2.00E − 04) but not in subcutaneous adipose
tissue (p = 1) [39]. Both loci were previously reported
in an Arab population but neither cg07839457
(p = 1.32E − 01) nor cg20399616 (BCAT1)
(p = 5.39E − 01) were significantly associated with adi-
posity in that study [15]. The 15 other EWAS included
in the systematic literature search (Additional file 1:
File S4) did not report cg07839457 (NLRC5) nor
cg20399616 (BCAT1).
Differentially methylated regions
One DMR was identified overlapping between obesity
(FWER = 0.112) and abdominal obesity (FWER = 0.198)
(Additional file 1: Figure S10 and Figure S11). This
DMR was annotated to chromosome 17 near gene
MIR4520A. This region contained five CpG sites of
the 450k array (cg13207180, cg24686902, cg08103988,
cg21358336, cg08750459) for obesity and four CpG
sites (cg24686902, cg08103988, cg21358336, cg08750
459) for abdominal obesity; none of which were sig-
nificantly associated with any of the anthropometric
indices in DMP analyses (FDR ranged between 0.71
and 0.91). A third DMR was associated with obesity
only (FWER = 0.124). It contained 13 CpG sites and
was annotated to be near gene RNF39 (Additional file 1:
Figure S12).
Fig. 1 Manhattan plot of epigenome wide p values for obesity (BMI ≥ 30 kg/m2). The red dotted line indicates epigenome-wide significance
according to FDR multiple test correction
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Replicated differentially methylated positions reported by
previous EWAS
In replication analysis on a subset of 1027 previously
reported 450k CpG sites associated with adiposity, we
found 15 DMPs associated with BMI at FDR < 0.05
(Table 5). Seven of these (cg00574958, cg25178683,
cg04927537, cg10927968, cg11024682, cg15871086,
cg06500161) were significantly associated with obesity
as well (Table 5). DMP cg00574958 annotated to the
5′ untranslated region of gene CPT1A, and DMPs
cg25178683 and cg04927537 both annotated to the
transcription start site of gene LGALS3BP, overlapped
with the DMPs found in the main epigenome-wide
analysis. These DMPs were directionally consistent
with the main epigenome-wide analysis. Using a simi-
lar approach, we found ten DMPs associated with WC
and six with abdominal obesity in the subset of CpG
sites from literature (Table 6). The previously men-
tioned DMPs on CPT1A and LGALS3BP (cg00574958,
cg25178683, cg04927537) were among these six loci
and showed directionally consistency with the DMPs
found in relation to BMI and obesity. Previous EWAS
have reported cg00574958 (CPT1A) in association with
both BMI and WC in Arab, European and African-
American populations [14–16, 40] while DMPs
cg04927537 and cg25178683 (LGALS3BP) were re-
ported in association with BMI and WC in Arab and
African American [14, 15].
Replicated differentially methylated regions reported in
non-African populations
None of the EWAS selected through our systematic lit-
erature search identified DMRs using similar methods.
One study identified regions based on mean methylation
index of CpG sites within a predefined region [41].
These five regions did not overlap with the DMRs iden-
tified in the present study.
Table 3 Differentially methylated positions for WC and abdominal obesity (WC ≥ 88 cm for women and ≥ 102 cm for men)
WC Abdominal obesity
CpG site CHR Position Nearest genea Featureb Delta
β valuec
p valued FDRd Delta
β valuec
p valued FDRd
cg07839457 16 57023022 NLRC5 TSS1500 0.0030 2.24E − 10 9.61E − 05 0.0340 6.86E − 05 8.17E − 01
cg00574958 11 68607622 CPT1A 5′ UTR − 0.0007 1.00E − 08 1.55E − 03 − 0.0135 1.52E − 08 6.54E − 03
cg25954539 6 31323677 HLA-B Body 0.0022 1.08E − 08 1.55E − 03 0.0316 5.78E − 05 7.75E − 01
cg08818207 6 32820355 TAP1 Body 0.0020 3.46E − 08 3.71E − 03 0.0303 5.14E − 05 7.75E − 01
cg04927537 17 76976091 LGALS3BP TSS200 0.0013 6.19E − 08 5.08E − 03 0.0195 4.23E − 05 7.75E − 01
cg22107533 15 45028083 TRIM69 TSS1500 0.0015 7.76E − 08 5.08E − 03 0.0252 2.14E − 04 8.17E − 01
cg01309328 6 32811253 PSMB8 Body 0.0014 8.69E − 08 5.08E − 03 0.0202 6.26E − 06 6.45E − 01
cg23533285 6 31322348 HLA-B Body 0.0015 9.47E − 08 5.08E − 03 0.0241 2.99E − 04 8.17E − 01
cg23570810 11 315102 IFITM1 Body 0.0018 1.12E − 07 5.35E − 03 0.0182 1.12E − 05 6.68E − 01
cg00218406 6 31431407 HCP5 3′ UTR 0.0022 1.66E − 07 7.12E − 03 0.0335 7.64E − 04 8.17E − 01
cg08099136 6 32811251 PSMB8 Body 0.0015 1.93E − 07 7.53E − 03 0.0180 3.23E − 04 8.17E − 01
cg11202345 17 76976057 LGALS3BP 1stExon 0.0011 2.15E − 07 7.70E − 03 0.0203 4.65E − 05 7.75E − 01
cg25178683 17 76976267 LGALS3BP TSS1500 0.0011 3.50E − 07 1.16E − 02 0.0136 1.41E − 05 6.68E − 01
cg01971407 11 313624 IFITM1 TSS1500 0.0010 4.69E − 07 1.44E − 02 0.0079 5.71E − 05 7.75E − 01
cg25843003 6 31431312 HCP5 3′ UTR 0.0009 7.03E − 07 2.01E − 02 0.0142 8.12E − 05 8.17E − 01
cg22940798 6 32805554 TAP2 Body 0.0010 1.03E − 06 2.75E − 02 0.0187 5.19E − 04 8.17E − 01
cg20399616 12 25055967 BCAT1 Body − 0.0012 1.20E − 06 2.97E − 02 − 0.0145 9.27E − 04 8.17E − 01
cg05439368 15 45028098 TRIM69 TSS1500 0.0015 1.25E − 06 2.97E − 02 0.0263 1.99E − 04 8.17E − 01
cg06538684 12 12511223 LOH12CR2 TSS1500 0.0011 1.62E − 06 3.53E − 02 0.0173 9.31E − 05 8.17E − 01
cg23235965 6 30459540 HLA-E Body 0.0011 1.64E − 06 3.53E − 02 0.0238 5.37E − 05 7.75E − 01
cg13558971 1 203597085 ATP2B4 5′ UTR − 0.0007 1.78E − 06 3.64E − 02 − 0.0092 1.82E − 03 8.17E − 01
cg13348877 18 78005237 PARD6G 1stExon − 0.0002 2.01E − 06 3.93E − 02 − 0.0021 8.15E − 05 8.17E − 01
cg08996521 3 50649994 CISH TSS1500 0.0005 2.52E − 06 4.70E − 02 0.0131 1.10E − 04 8.17E − 01
aCpGs are located in the gene if no distance is indicated
bBased on manifest feature annotation Illumina. IGR, intergenic region
cNegative beta values indicate lower DNA methylation (hypo-methylation) in cases compared with controls
dp values and FDR corresponding to M values. Table is sorted on WC associated p values. All significant hits for both outcomes are included
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Pathway analyses
Pathway analyses resulted in 67 enriched GO categories in
relation to BMI and 61 in relation to WC. Twenty-six of
these BMI GO categories contained either one or more
DMPs associated with BMI and obesity (Additional file 1:
Table S13-A). Pathways were mostly involved in immune
function, cell signalling and regulation. Out of the WC
pathways, five pathways contained the DMP annotated to
gene CPT1A associated with WC and abdominal obesity
(Additional file 1: Table S13-B). These pathways were re-
lated to peptide transport and regulation.
Discussion
In the present study, we report the first EWAS for
adiposity among sub-Saharan Africans using a sample of
Ghanaians from the RODAM study. We found DMP
cg00574958 annotated to gene CPT1A to be significantly
associated with BMI, WC, obesity and abdominal obesity.
DMPs cg07839457 and cg20399616, annotated to genes
NLRC5 and BCAT1, respectively, were associated with
BMI, WC and obesity but not with abdominal obesity.
These two DMPs are novel adiposity loci as they have not
previously been reported in any EWAS for adiposity.
Direct measurement of adiposity, for example by com-
puted tomography, is rarely feasible in the field epidemio-
logical studies. Therefore, we evaluated two commonly
used epidemiological indicators of adiposity, namely BMI
and WC both continuous and dichotomised. BMI is an
index for generalized adiposity or overall body size and is
most widely used. WC is thought to better capture the
metabolic complications of adiposity [42]. WC has been
found to correlate well with abdominal imaging [43] and
is associated with metabolic diseases such as type 2
diabetes [44]. Fourteen of the 41 DMPs (34%) overlapped
between BMI and WC (Fig. 2) and were directionally
consistent. This is considerably lower than the 74% DMP
Table 4 Odds ratios for obesity and abdominal obesity Differentially Methylated Positions (DMPs)
Obesity Abdominal obesity
CpG CHR Position Genea Featureb ORc 95% CI Attributable trait variance (%) ORc 95% CI Attributable trait variance (%)
cg07839457 16 57023022 NLRC5 TSS1500 1.04 1.02–1.06 2.4 1.03 1.01–1.06 1.4
cg00574958 11 68607622 CPT1A 5′ UTR 0.85 0.80–0.91 6.1 0.84 0.79–0.90 5.6
cg20399616 12 25055967 BCAT1 Body 0.94 0.90–0.98 1.6 0.96 0.91–1.00 0.7
aCpGs are located in the gene if no distance is indicated
bBased on manifest feature annotation Illumina
cOdds ratios are per 1% increase in DNA methylation
Fig. 2 Venn diagram of overlapping genes in or near differentially methylated positions (DMPs) in relation to BMI, WC, obesity and
abdominal obesity
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overlap between BMI and WC previously reported in
African Americans [14]. A possible explanation for
this discrepancy is that BMI and WC identify differ-
ent individuals at risk in our Ghanaian population as
is shown by the fact that there were 132 more with
abdominal obesity than with general adiposity in this
study sample. Previous studies have shown differ-
ences in fat distribution between African descent and
European populations characterized by less abdominal fat
in Africans [45]. A previous study in Ghanaians found
poor discriminative ability of BMI for type 2 diabetes
compared with indices for abdominal obesity [46].
Potentially, increases in WC are more pronounced in
this population than increases in BMI, which might
underlie the high type 2 diabetes burden in this
population [3]. Our finding that in Ghanaians, the
DMP annotated to gene CPT1A was associated
strongly with abdominal obesity suggests the need to
explore the role of CPT1A variation in DNA methy-
lation related to increases in WC and increased risk
for type 2 diabetes.
CPT1A, or carnitine palmitoyltransferase 1A, has been
reported in relation to BMI, obesity and weight gain in
both GWAS and EWAS of multiple populations [14–16].
The DMP cg00574958 is annotated to the 5′ untranslated
region, a region important in regulation, of the CPT1A
gene. The CPT1A gene codes for the carnitine palmitoyl-
transferase 1 enzyme, which is crucial in fatty acid beta-
oxidation [47]. Beta oxidation is a catabolic process in
fatty acid metabolism. We observed hypo-methylation at
cg00574958 for higher BMI and WC. A previous study
has shown that higher DNA methylation at cg00574958
correlated negatively with CPT1A expression in blood
[48]. Hypo-methylation at cg00574958 could thus be in-
volved in increased expression of CPT1A and subsequent
increased enzyme production. This suggests more beta
oxidation is taking place in those with more adiposity.
Hypo-methylation at cg00574958 could be the result of
the high fat mass which requires a more active fatty acid
metabolism. This is in line with previous studies that have
reported modifications in DNA methylation as a result of
changes in lipid metabolism due to adiposity rather than
Fig. 3 Differentially methylated position (DMP) annotated to gene CPT1A associated with BMI, WC, obesity and abdominal obesity. The DMP is
annotated as the CpG site in the red square. A 5-kb region around the DMP was visualized
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as a cause [49]. In our study population, CPT1A attributed
to 6.1% of the variance in obesity and 5.6% of the variance
in abdominal obesity.
NLRC5 (NLR family CARD domain containing 5)
and BCAT1 (branched chain amino acid transaminase 1)
are novel adiposity candidate loci as they have not
been reported in previous EWAS. In pathway analyses
(Additional file 1: Table S13-A and S13-B), we found
that NLR5 is involved in multiple immune response
pathways. The NLRC5 gene regulates the expression
of major histocompatibility complex (MHC) class I genes
[50]. MHC class I molecules play an important role in
immune function, in particular in the activation of CD8+
T cells against viral infections. CD8+ T cells also play an
essential role in onset of adipose tissue inflammation [51].
Other studies have shown that NLRC5 can be upregulated
in response to inflammatory stimulation [52]. Excess
adipose tissue has regularly been associated with induced
inflammation [53]. DMP cg07839457 located 1.5 kb up-
stream of the transcription start site (TSS) of NLRC5 was
Fig. 4 Differentially methylated position (DMP) annotated to gene NLRC5 associated with BMI, obesity and WC. The DMP is annotated as the CpG
site in the red square. A 5-kb region around the DMP was visualized
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found in our study to be hyper-methylated for higher BMI
and WC, and 7.1% hyper-methylated in those with obesity
compared with those without (Tables 2 and 3). Hyper-
methylation of TSS regions is in general associated with
long-term silencing [54] which could imply lower expres-
sion of NLRC5 gene in adiposity. Functional studies are
needed to investigate the role of the NLRC gene in
adiposity among sub-Saharan Africans.
DMP cg20399616 annotated to gene BCAT1 was hypo-
methylated in relation to BMI, WC and obesity. BCAT1
encodes for a protein that catalyses catabolism of amino
acids [55]. This gene has shown very low methylation
levels in blood in patients with colorectal cancer [56] and
is being explored to be used as biomarker in colorectal
cancer assays [57]. BCAT1 has also been found hypo-
methylated in other cancer types such as ovarian cancer
[58]. The relative risk of several types of cancer has been
found higher in obese compared with non-obese [59]. Our
data suggest that this could potentially be mediated by
DNA methylation variations caused by adiposity.
Fig. 5 Differentially methylated position (DMP) annotated to gene BCAT1 associated with BMI, obesity and WC. The DMP is annotated as the CpG
site in the red square. A 5-kb region around the DMP was visualized
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Little is known about the translatability of EWAS
findings among Europeans to sub-Saharan Africans.
The few EWAS conducted in non-European popula-
tions identified novel loci involved in adiposity in
African Americans and Arabs [14, 15, 18]. These
studies found transferability between European and
other populations to be relatively low. Out of 47
EWAS associations reported in Europeans, seven were
replicated in Arab populations and showed heterogen-
eity in effects between both populations for all loci
except CPT1A [15]. Transferability of findings among
African Americans to Europeans was somewhat
higher: 62% of epigenome-wide DMPs in African
Americans were replicated in Europeans [14]. The top
Table 5 Replicated differentially methylated positions (DMPs) associated with BMI and obesity reported by previous EWAS
BMI Obesity
CpG site CHR Position Nearest gene
(distance)a
Featureb Beta differencec p valued FDRd Beta differencec p valued FDRd
cg00574958 11 68607622 CPT1A 5′ UTR − 0.0014 1.47E − 07 1.42E − 04 − 0.0189 2.58E − 10 2.49E − 07
cg25178683 17 76976267 LGALS3BP TSS1500 0.0019 1.20E − 06 4.62E − 04 0.0195 8.51E − 05 2.74E − 02
cg04927537 17 76976091 LGALS3BP TSS200 0.0026 1.43E − 06 4.62E − 04 0.0286 6.85E − 06 3.31E − 03
cg10927968 11 1807333 CTSD (33351) IGR 0.0015 2.58E − 05 6.24E − 03 0.0135 2.71E − 04 4.15E − 02
cg17320136 5 10567905 ANKRD33B Body 0.0015 7.47E − 05 1.44E − 02 0.0109 9.60E − 04 1.03E − 01
cg03345232 14 92981121 RIN3 Body 0.0022 1.29E − 04 1.78E − 02 0.0193 2.08E − 03 1.66E − 01
cg08726900 16 89550474 ANKRD11 5′ UTR − 0.0029 1.40E − 04 1.78E − 02 − 0.0237 3.85E − 03 2.33E − 01
cg11024682 17 17730094 SREBF1 Body 0.0009 1.52E − 04 1.78E − 02 0.0119 1.80E − 04 3.47E − 02
cg15871086 18 56526595 ZNF532 (− 3466) IGR 0.0011 1.66E − 04 1.78E − 02 0.0115 1.78E − 04 3.47E − 02
cg18335991 15 74724562 SEMA7A Body 0.0019 2.19E − 04 2.12E − 02 0.0175 2.24E − 03 1.66E − 01
cg07504977 10 102131012 LINC00263 (− 2321) IGR 0.0018 2.57E − 04 2.26E − 02 0.0191 8.32E − 04 1.01E − 01
cg27243685 21 43642366 ABCG1 Body 0.0005 4.50E − 04 3.46E − 02 0.0054 2.41E − 03 1.66E − 01
cg17439800 1 208056493 CD34 (− 3390) IGR 0.0016 4.65E − 04 3.46E − 02 0.0123 2.06E − 02 5.38E − 01
cg06500161 21 43656587 ABCG1 Body 0.0005 5.46E − 04 3.77E − 02 0.0077 3.00E − 04 4.15E − 02
cg03546163 6 35654363 FKBP5 5′ UTR 0.0019 6.96E − 04 4.49E − 02 0.0181 4.18E − 03 2.38E − 01
aCpGs are located in the gene if no distance is indicated. Distance is expressed in kilobase
bBased on manifest feature annotation Illumina. IGR, intergenic region
cNegative beta values indicate lower DNA methylation (hypo-methylation) in cases compared with controls
dp values and FDR corresponding to M values. Table is sorted on BMI associated p values. All significant hits for both outcomes are included
Table 6 Replicated differentially methylated positions (DMPs) associated with WC and abdominal obesity reported by previous EWAS
WC Abdominal obesity
CpG site CHR Position Nearest gene
(distance)a
Featureb Beta differencec p valued FDRd Beta differencec p valued FDRd
cg00574958 11 68607622 CPT1A 5′ UTR − 0.0007 1.02E − 08 9.87E − 06 −0.0135 1.55E − 08 1.49E − 05
cg04927537 17 76976091 LGALS3BP TSS200 0.0013 6.74E − 08 3.26E − 05 0.0195 4.44E − 05 1.07E − 02
cg25178683 17 76976267 LGALS3BP TSS1500 0.0011 3.96E − 07 1.28E − 04 0.0136 1.54E − 05 7.22E − 03
cg07504977 10 102131012 LINC00263 (− 2321) IGR 0.0010 1.60E − 05 3.87E − 03 0.0240 2.24E − 05 7.22E − 03
cg18335991 15 74724562 SEMA7A Body 0.0009 2.22E − 05 4.30E − 03 0.0147 3.75E − 04 7.24E − 02
cg27243685 21 43642366 ABCG1 Body 0.0004 7.58E − 05 1.22E − 02 0.0037 1.72E − 02 3.77E − 01
cg10927968 11 1807333 CTSD IGR 0.0007 9.42E − 05 1.30E − 02 0.0082 1.27E − 02 3.77E − 01
cg06500161 21 43656587 ABCG1 Body 0.0003 2.15E − 04 2.60E − 02 0.0033 3.47E − 03 2.76E − 01
cg13123009 6 31681882 LY6G6E TSS200 0.0004 3.22E − 04 3.46E − 02 0.0074 3.65E − 03 2.76E − 01
cg17439800 1 208056493 CD34 IGR 0.0006 5.09E − 04 4.92E − 02 0.0205 5.83E − 04 9.39E − 02
aCpGs are located in the gene if no distance is indicated. Distance is expressed in kilobase
bBased on manifest feature annotation Illumina. IGR, intergenic region
cNegative beta values indicate lower DNA methylation (hypo-methylation) in cases compared with controls
dp values and FDR corresponding to M values. Table is sorted on WC associated p values. All significant hits for both outcomes are included
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DMPs in replication again included CPT1A. In the
present study, we found transferability with BMI for
15 previously reported DMPs and with WC for 10 pre-
viously reported DMPs on adiposity. These loci, in
particular the DMP annotated to CPT1A, may play a
role in adiposity across populations.
A potential limitation to our study is the use of
blood samples as DNA methylation is tissue specific.
However, several studies have shown moderate to
strong correlations between blood tissue DNA methy-
lation and other tissue types such as subcutaneous fat
[49]. Specifically, the methylation level of gene CPT1A
showed cross-tissue agreement between blood and
adipose tissue in previous studies [14]. Another limi-
tation to our study is that due to the cross-sectional
nature of our study, we cannot make statements
about causality. A recent meta-analyses showed that
changes in DNA methylation were rather the conse-
quence of adiposity than the cause [49]. Evidence
from intervention studies strengthens this notion. For
example, a study on weight loss found 432 DMPs be-
fore dietary intervention of which 15 DMPs remained
at the end of the intervention when participants had
lost weight [60]. Other studies have shown that DNA
methylation changes induced by a high-fat diet can be
partly reversed after a 6–8-week washout period [61].
The DMPs we identified also seemed the result of
adiposity given the biological plausibility of the genes
involved. A possible limitation of the present study is
the possibility that some of the hits reported are due
to genetic (e.g. SNPs) rather than epigenetic variation.
Unfortunately, we do not yet have GWAS SNP data
on the RODAM cohort that would allow us directly
test this hypothesis. Furthermore, we observed some
inflation in evaluation of QQ plots (Additional file 1:
File S2). However, methods for inflation correction
(Additional file 1: File S3) did not substantially im-
prove model fitting nor did it alter our results regard-
ing the DMPs identified. The results of this EWAS
should be confirmed in follow-up studies to disentan-
gle the etiological role of DMPs we identified. These
follow-up studies should include translational research
as well as a characterization of the role of environ-
ment versus genetics in observed DNA methylation
findings.
Conclusions
In conclusion, we report the first EWAS on adiposity
among sub-Saharan Africans. Notably, we found
three DMPs or loci (CPT1A, NLRC5 and BCAT1)
that showed epigenome-wide significance with both
obesity and abdominal obesity. Translational studies
and longitudinal study designs are warranted to de-
termine the role of these DNA methylation variants
in the high burden of adiposity among sub-Saharan
Africans.
Additional file
Additional file 1: Additional methods, quality control, sensitivity
analyses and supplementary results. (ZIP 1243 kb)
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